单抗

Search documents
短期震荡蓄势不改中期向好格局
British Securities· 2025-07-08 04:37
Core Viewpoints - The current market is experiencing a phase of consolidation rather than stagnation, with expectations for future upward movement as economic recovery and corporate earnings improve [2][9][10] - The market is characterized by a structural trend, with certain sectors showing potential for independent performance due to policy support and earnings growth [5][9] Market Overview - On the recent trading day, the Shanghai Composite Index showed relative strength, while the ChiNext and Shenzhen Composite Indexes declined, indicating a divergence among the three major indexes [2][11] - The total trading volume across both exchanges decreased to 1.2 trillion yuan, reflecting a cautious market sentiment [6][11] Sector Performance - The electricity sector saw significant gains, driven by the successful operation of a major thermal power plant and a favorable coal price environment, leading to positive earnings growth for many companies in this sector [7] - The cross-border payment sector also experienced an uptick, supported by the central bank's initiatives to enhance cross-border payment systems between mainland China and Hong Kong [8] Investment Opportunities - Three main investment themes are identified: 1. Stocks with better-than-expected interim performance, focusing on those with anticipated earnings improvements [3][10] 2. Technology sectors including military, robotics, AI, semiconductors, and digital economy, with a cautionary note on the need for thorough fundamental analysis to avoid overvalued stocks [3][10] 3. Rebound opportunities in sectors like new energy and brokerage firms, suggesting a strategy of buying on dips [3][10]
创业板指盘初涨幅扩大至1%,上证指数现涨0.15%;大医药概念集体反弹,CRO、创新药、单抗、重组蛋白等概念走强;全市约3800股上涨,1300股下跌,主力资金净流出超20亿元。
news flash· 2025-07-08 01:55
Group 1 - The ChiNext Index initially increased by 1%, while the Shanghai Composite Index rose by 0.15% [1] - The large healthcare sector experienced a collective rebound, with strong performance in CRO, innovative drugs, monoclonal antibodies, and recombinant proteins [1] - Approximately 3,800 stocks in the market rose, while 1,300 stocks declined, indicating a net outflow of over 2 billion yuan from major funds [1]